Lorazepam-Based Sedation Reduces Agitation in Advanced Cancer Delirium
In a randomized trial published in JAMA Oncology, researchers found that scheduled sedatives, particularly lorazepam-based regimens, may help reduce persistent restlessness and agitation in patients with advanced cancer and delirium in the palliative care setting. This suggests that proactive, scheduled use of these medications may reduce the need for additional rescue treatments during episodes of breakthrough restlessness or agitation.